Genmab A/S (NASDAQ:GMAB) Upgraded at Wall Street Zen

Key Points

• Genmab A/S has been upgraded from a "hold" rating to a "buy" rating by Wall Street Zen, indicating increased investor confidence in the company's stock.
• HC Wainwright and Truist Financial have also issued "buy" ratings with adjusted price targets of $37.00 and $46.00 respectively, showcasing varying outlooks among analysts.
• The company's recent quarterly earnings report revealed earnings per share of $0.31, exceeding analyst expectations, but the revenue of $715 million fell short of the $5.17 billion forecast.

Genmab A/S (NASDAQ:GMAB - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Monday.

Other equities research analysts also recently issued research reports about the company. Sanford C. Bernstein downgraded Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Truist Financial raised their price objective on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. Finally, HC Wainwright reissued a "buy" rating and set a $37.00 target price (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $37.80.

Genmab A/S Stock Down 1.2%

Shares of NASDAQ GMAB traded down $0.27 during trading on Monday, reaching $22.00. The company had a trading volume of 146,027 shares, compared to its average volume of 1,449,931. The stock has a market cap of $14.12 billion, a P/E ratio of 12.50, a PEG ratio of 6.87 and a beta of 0.94. The company's fifty day moving average price is $21.62 and its 200-day moving average price is $20.83. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $28.56.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.08. The business had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. As a group, equities analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

Institutional Trading of Genmab A/S

Hedge funds and other institutional investors have recently made changes to their positions in the business. Headlands Technologies LLC lifted its holdings in shares of Genmab A/S by 1,525.0% during the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock worth $31,000 after purchasing an additional 1,464 shares during the period. CWM LLC raised its stake in shares of Genmab A/S by 50.5% during the 2nd quarter. CWM LLC now owns 1,797 shares of the company's stock valued at $37,000 after buying an additional 603 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Genmab A/S by 124.3% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock valued at $38,000 after buying an additional 1,070 shares during the period. Barclays PLC grew its holdings in Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after acquiring an additional 2,285 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Genmab A/S during the fourth quarter valued at approximately $60,000. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.